CDT - רווח תפעולי לפני פחת Conduit Pharmaceuticals Inc.

Conduit Pharmaceuticals focuses on licensing drugs for the therapy of autoimmune kidney and lung pathologies. Management is implementing the IDP model to accelerate the commercialization of immunological assets. The operating profit summary demonstrates the current parameter 0.00, which characterizes the cash flow before interest. Optimized supply chains for chemical formulas serve as a guarantee for the stable conduct of clinical trials.

For Conduit Pharmaceuticals (CDT), whose valuation is based on AstraZeneca licenses in the absence of sales, an EBITDA level of 0.00 reflects the actual cash flow from core operations excluding depreciation and interest. This indicator allows investors to strip away GAAP accounting adjustments to assess the real financial stability of the ecosystem prior to the completion of clinical trials and the receipt of FDA and EMA approvals.